Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to evaluate the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo as add-on therapy to mood stabilizers in the treatment of manic episodes associated with bipolar disorder.


Clinical Trial Description

Risperidone, widely used in the treatment of schizophrenia, has been shown to be effective in the treatment of manic and mixed episodes associated with bipolar disorders. Antipsychotic drugs like risperidone have also been used as additional therapeutic agents in the treatment of patients who are not responsive to mood stabilizers alone. This is a randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of risperidone compared with placebo, as an addition to mood stabilizing drugs in the treatment of patients experiencing manic episodes. Treatment of one group of patients with haloperidol is used as an internal control in the trial. The study has two phases: a double-blind treatment phase (3 weeks) and an open-label phase (10 weeks). During the double-blind treatment phase patients receive risperidone, haloperidol, or placebo tablets to be taken once a day at gradually increasing doses (adjusted to 1 to 6 mg/day for risperidone and 2 to 12 mg/day for haloperidol), while continuing treatment with a mood stabilizer (lithium or valproate). In the open-label phase all patients receive risperidone with the dosage gradually adjusted to achieve optimal effectiveness (dose range of 0 to 6 mg/day); in this phase patients continue therapy with a mood stabilizer (lithium, valproate, or, for this phase only, carbamazepine). The primary measure of effectiveness is the change in the Young Mania Rating Scale (YMRS) total score from baseline to end of double-blind treatment. Additional assessments of effectiveness include the Brief Psychiatric Rating Scale (BPRS); the Clinical Global Impression (CGI), which evaluates the change in severity of the disorder; and the Hamilton Depression Rating Scale (HAMD). Safety assessments include the incidence of adverse events throughout the study; measurement of vital signs (pulse and blood pressure) and evaluation of the presence and severity of extrapyramidal symptoms by the Extrapyramidal Symptom Rating Scale (ESRS) at specified intervals; and clinical laboratory tests (hematology, biochemistry, urinalysis) before study initiation, at completion of double-blind treatment, and at the end of study. The study hypothesis is that daily treatment with risperidone as add-on therapy provides better effectiveness than placebo, as measured by Young Mania Rating Scale scores, in the treatment of the manic phase of bipolar disorder. Double-blind (daily doses, taken orally once a day) - Days 1 and 2: risperidone 2 mg, haloperidol 4 mg, or placebo. Days 3 and 4: risperidone 1 - 4 mg, haloperidol 2 - 8 mg, or placebo. Days 5 - 21: risperidone 1 - 6 mg, haloperidol 2 - 21 mg, or placebo. Open-label: risperidone 0 - 6 mg/day for 10 weeks. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00253149
Study type Interventional
Source Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contact
Status Completed
Phase Phase 3
Completion date April 1999

See also
  Status Clinical Trial Phase
Recruiting NCT05537376 - A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness N/A
Completed NCT00240721 - A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder Phase 3
Completed NCT02242669 - Enhancing Outcomes, Reducing Costs: Evaluating Peer Support for Mood Disorders N/A
Completed NCT01821469 - Functional Correlates of Bipolar Disorders and Effects of the Psychoeducation. an fMRI Study N/A
Completed NCT00888264 - A NIS Evaluating the Treatment Patterns of Atypical Antipsychotics in Patients Diagnosed With Bipolar I or II Disorder N/A
Completed NCT02807688 - Physical Co-morbidity, Poor Health Behaviour and Health Promotion in Verona Patients With Functional Psychoses N/A
Completed NCT00253162 - A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol Phase 3
Not yet recruiting NCT02904083 - Study of the Effectiveness of Specific Training of Health Professionals on Adherence in Bipolar Disorder N/A
Completed NCT01729650 - Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor) N/A
Recruiting NCT02843906 - Cognitive, Morphological and Neurobiological Progressive Aspects in Bipolar Disorders in the Elderly: Toward to a Neurodegenerescence Detection? N/A
Completed NCT01377896 - The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours N/A
Completed NCT00453804 - Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI) Phase 4
Terminated NCT00047567 - Open-label Adjunctive Zonisamide for Bipolar Disorder Phase 4
Completed NCT03028545 - Representations and Strategies for Recovery N/A
Completed NCT00156325 - Escitalopram as a Mood Stabilizer for Bipolar II Disorder Phase 2
Completed NCT06034769 - Oral and Jaw Health in Bipolar Patients
Terminated NCT02936466 - Evaluation of a Serious Game for Patients With Bipolar Disorder Involved in a Psychoeducation Group N/A
Completed NCT00845988 - Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders Phase 4
Completed NCT00257075 - A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder Phase 3
Recruiting NCT01188395 - Bipolar Disorder With Alcoholism in Han Chinese N/A